Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 118

1.

Evolution of Experimental Design and Research Techniques in HIV-1 Reservoir Studies: A Systematic Review.

De-Scheerder MA, Depelseneer B, Vandekerckhove L, Wim T.

AIDS Rev. 2020;22(1):16-24. doi: 10.24875/AIDSRev.M20000028.

PMID:
32167504
2.

Underestimated effect of intragenic HIV-1 DNA methylation on viral transcription in infected individuals.

Kint S, Trypsteen W, De Spiegelaere W, Malatinkova E, Kinloch-de Loes S, De Meyer T, Van Criekinge W, Vandekerckhove L.

Clin Epigenetics. 2020 Feb 28;12(1):36. doi: 10.1186/s13148-020-00829-1.

3.

Rapid viral rebound after analytical treatment interruption in patients with very small HIV reservoir and minimal on-going viral transcription.

Pannus P, Rutsaert S, De Wit S, Allard SD, Vanham G, Cole B, Nescoi C, Aerts J, De Spiegelaere W, Tsoumanis A, Couttenye MM, Herssens N, De Scheerder MA, Vandekerckhove L, Florence E.

J Int AIDS Soc. 2020 Feb;23(2):e25453. doi: 10.1002/jia2.25453.

4.

Evaluating predictive markers for viral rebound and safety assessment in blood and lumbar fluid during HIV-1 treatment interruption.

De Scheerder MA, Van Hecke C, Zetterberg H, Fuchs D, De Langhe N, Rutsaert S, Vrancken B, Trypsteen W, Noppe Y, Van Der Gucht B, Pelgrom J, Van Wanzeele F, Palmer S, Lemey P, Gisslén M, Vandekerckhove L.

J Antimicrob Chemother. 2020 Feb 13. pii: dkaa003. doi: 10.1093/jac/dkaa003. [Epub ahead of print]

PMID:
32053203
5.

Emerging PCR-Based Techniques to Study HIV-1 Reservoir Persistence.

Lambrechts L, Cole B, Rutsaert S, Trypsteen W, Vandekerckhove L.

Viruses. 2020 Jan 28;12(2). pii: E149. doi: 10.3390/v12020149. Review.

6.

Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients.

Orkin C, Eron JJ, Rockstroh J, Podzamczer D, Esser S, Vandekerckhove L, Van Landuyt E, Lathouwers E, Hufkens V, Jezorwski J, Opsomer M; AMBER study group.

AIDS. 2020 Apr 1;34(5):707-718. doi: 10.1097/QAD.0000000000002463.

PMID:
31833849
7.

Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial.

Dickinson L, Gurjar R, Stöhr W, Bonora S, Owen A, D'Avolio A, Cursley A, Molina JM, Fäetkenheuer G, Vandekerckhove L, Di Perri G, Pozniak A, Richert L, Raffi F, Boffito M; NEAT001/ANRS143 Study Group .

J Antimicrob Chemother. 2020 Mar 1;75(3):628-639. doi: 10.1093/jac/dkz479.

PMID:
31754703
8.

Long non-coding RNAs and latent HIV - A search for novel targets for latency reversal.

Trypsteen W, White CH, Mukim A, Spina CA, De Spiegelaere W, Lefever S, Planelles V, Bosque A, Woelk CH, Vandekerckhove L, Beliakova-Bethell N.

PLoS One. 2019 Nov 11;14(11):e0224879. doi: 10.1371/journal.pone.0224879. eCollection 2019.

9.

HIV Rebound Is Predominantly Fueled by Genetically Identical Viral Expansions from Diverse Reservoirs.

De Scheerder MA, Vrancken B, Dellicour S, Schlub T, Lee E, Shao W, Rutsaert S, Verhofstede C, Kerre T, Malfait T, Hemelsoet D, Coppens M, Dhondt A, De Looze D, Vermassen F, Lemey P, Palmer S, Vandekerckhove L.

Cell Host Microbe. 2019 Sep 11;26(3):347-358.e7. doi: 10.1016/j.chom.2019.08.003. Epub 2019 Aug 27.

PMID:
31471273
10.

Evaluation of HIV-1 reservoir levels as possible markers for virological failure during boosted darunavir monotherapy.

Rutsaert S, De Spiegelaere W, De Clercq L, Vandekerckhove L.

J Antimicrob Chemother. 2019 Oct 1;74(10):3030-3034. doi: 10.1093/jac/dkz269.

PMID:
31314108
11.
12.

Early treated HIV-1 positive individuals demonstrate similar restriction factor expression profile as long-term non-progressors.

Van Hecke C, Trypsteen W, Malatinkova E, De Spiegelaere W, Vervisch K, Rutsaert S, Kinloch-de Loes S, Sips M, Vandekerckhove L.

EBioMedicine. 2019 Mar;41:443-454. doi: 10.1016/j.ebiom.2019.02.006. Epub 2019 Feb 12. No abstract available.

13.

In-vitro viral suppressive capacity correlates with immune checkpoint marker expression on peripheral CD8+ T cells in treated HIV-positive patients.

Pannus P, Adams P, Willems E, Heyndrickx L, Florence E, Rutsaert S, De Spiegelaere W, Vandekerckhove L, Seguin-Devaux C, Vanham G.

AIDS. 2019 Mar 1;33(3):387-398. doi: 10.1097/QAD.0000000000002068.

PMID:
30702513
14.

Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected Individuals.

Morón-López S, Navarro J, Jimenez M, Rutsaert S, Urrea V, Puertas MC, Torrella A, De Clercq L, Ribas BP, Gálvez C, Salgado M, Vandekerckhove L, Blanco J, Crespo M, Martinez-Picado J.

Clin Infect Dis. 2019 Sep 27;69(8):1320-1328. doi: 10.1093/cid/ciy1095.

15.

Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction.

Tulkens J, Vergauwen G, Van Deun J, Geeurickx E, Dhondt B, Lippens L, De Scheerder MA, Miinalainen I, Rappu P, De Geest BG, Vandecasteele K, Laukens D, Vandekerckhove L, Denys H, Vandesompele J, De Wever O, Hendrix A.

Gut. 2020 Jan;69(1):191-193. doi: 10.1136/gutjnl-2018-317726. Epub 2018 Dec 5. No abstract available.

16.

In-depth validation of total HIV-1 DNA assays for quantification of various HIV-1 subtypes.

Rutsaert S, De Spiegelaere W, Van Hecke C, De Scheerder MA, Kiselinova M, Vervisch K, Trypsteen W, Vandekerckhove L.

Sci Rep. 2018 Nov 22;8(1):17274. doi: 10.1038/s41598-018-35403-6.

17.

Predictors of virological failure in HIV-1-infected patients switching to dolutegravir maintenance monotherapy.

Wijting I, Rutsaert SL, Rokx C, Burger DM, Verbon A, van Kampen J, Boucher C, Rijnders B, Vandekerckhove L.

HIV Med. 2019 Jan;20(1):63-68. doi: 10.1111/hiv.12675. Epub 2018 Sep 30.

18.

Evaluation of bisulfite kits for DNA methylation profiling in terms of DNA fragmentation and DNA recovery using digital PCR.

Kint S, De Spiegelaere W, De Kesel J, Vandekerckhove L, Van Criekinge W.

PLoS One. 2018 Jun 14;13(6):e0199091. doi: 10.1371/journal.pone.0199091. eCollection 2018.

19.

Diabetes-Induced Cardiomyocyte Passive Stiffening Is Caused by Impaired Insulin-Dependent Titin Modification and Can Be Modulated by Neuregulin-1.

Hopf AE, Andresen C, Kötter S, Isić M, Ulrich K, Sahin S, Bongardt S, Röll W, Drove F, Scheerer N, Vandekerckhove L, De Keulenaer GW, Hamdani N, Linke WA, Krüger M.

Circ Res. 2018 Jul 20;123(3):342-355. doi: 10.1161/CIRCRESAHA.117.312166. Epub 2018 May 14.

PMID:
29760016
20.

Long-term use of darunavir/ritonavir-containing regimens in daily practice in Belgium: retrospective observational cohort data of 1701 HIV-patients.

De Wit S, Florence E, Vandekerckhove L, Vandercam B, Goffard JC, Van Wijngaerden E, Moutschen M, Demeester R, Thilakarathne P, Piryns H; BREACH* Consortium.

Acta Clin Belg. 2018 Oct;73(5):341-347. doi: 10.1080/17843286.2018.1458428. Epub 2018 Apr 6.

21.

Highlights from the HIV Cure and Reservoir Symposium, 11-12 September 2017, Ghent, Belgium.

Kint S, Van Hecke C, Cole B, Vandekerckhove L, Sips M.

J Virus Erad. 2018 Jan 1;4(1):55-58.

22.

Digital PCR as a tool to measure HIV persistence.

Rutsaert S, Bosman K, Trypsteen W, Nijhuis M, Vandekerckhove L.

Retrovirology. 2018 Jan 30;15(1):16. doi: 10.1186/s12977-018-0399-0. Review.

23.

Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.

Molina JM, Grund B, Gordin F, Williams I, Schechter M, Losso M, Law M, Ekong E, Mwelase N, Skoutelis A, Wiselka MJ, Vandekerckhove L, Benfield T, Munroe D, Lundgren JD, Neaton JD; INSIGHT START study group.

Lancet HIV. 2018 Apr;5(4):e172-e180. doi: 10.1016/S2352-3018(18)30003-1. Epub 2018 Jan 16.

PMID:
29352723
24.

Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance.

Fun A, Leitner T, Vandekerckhove L, Däumer M, Thielen A, Buchholz B, Hoepelman AIM, Gisolf EH, Schipper PJ, Wensing AMJ, Nijhuis M.

Retrovirology. 2018 Jan 5;15(1):1. doi: 10.1186/s12977-017-0384-z.

25.

Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort.

Roen A, Laut K, Pelchen-Matthews A, Borodulina E, Caldeira L, Clarke A, Clotet B, d'Arminio Monforte A, Fätkenheuer G, Gatell Artigas JM, Karpov I, Kuznetsova A, Kyselyova G, Mozer-Lisewska I, Mulcahy F, Ragone L, Scherrer A, Uzdaviniene V, Vandekerckhove L, Vannappagari V, Ostergaard L, Mocroft A; EuroSIDA study.

HIV Med. 2018 Apr;19(4):252-260. doi: 10.1111/hiv.12573. Epub 2017 Dec 22.

PMID:
29271606
26.

Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?

Mocroft A, Laut K, Reiss P, Gatell J, Ormaasen V, Cavassini M, Hadziosmanovic V, Mansinho K, Pradier C, Vasylyev M, Mitsura V, Vandekerckhove L, Ostergaard L, Clarke A, Degen O, Mulcahy F, Castagna A, Sthoeger Z, Flamholc L, Sedláček D, Mozer-Lisewska I, Lundgren JD; EuroSIDA Study.

AIDS. 2018 Jan 14;32(2):205-215. doi: 10.1097/QAD.0000000000001684.

PMID:
29112060
27.

Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial.

Cahn P, Kaplan R, Sax PE, Squires K, Molina JM, Avihingsanon A, Ratanasuwan W, Rojas E, Rassool M, Bloch M, Vandekerckhove L, Ruane P, Yazdanpanah Y, Katlama C, Xu X, Rodgers A, East L, Wenning L, Rawlins S, Homony B, Sklar P, Nguyen BY, Leavitt R, Teppler H; ONCEMRK Study Group.

Lancet HIV. 2017 Nov;4(11):e486-e494. doi: 10.1016/S2352-3018(17)30128-5. Epub 2017 Sep 11.

PMID:
28918877
28.

Inhibitory actions of the NRG-1/ErbB4 pathway in macrophages during tissue fibrosis in the heart, skin, and lung.

Vermeulen Z, Hervent AS, Dugaucquier L, Vandekerckhove L, Rombouts M, Beyens M, Schrijvers DM, De Meyer GRY, Maudsley S, De Keulenaer GW, Segers VFM.

Am J Physiol Heart Circ Physiol. 2017 Nov 1;313(5):H934-H945. doi: 10.1152/ajpheart.00206.2017. Epub 2017 Aug 19.

29.

Fight fire with fire: Gene therapy strategies to cure HIV.

Huyghe J, Magdalena S, Vandekerckhove L.

Expert Rev Anti Infect Ther. 2017 Aug;15(8):747-758. doi: 10.1080/14787210.2017.1353911. Epub 2017 Jul 14. Review.

PMID:
28692305
30.

Highlights from the 24th Conference on Retroviruses and Opportunistic Infections: 13-16 February 2017, Seattle, Washington, USA.

Crowell TA, Lyall H, Malatinkova E, Bhagani S, Hsu D, Colby DJ, Polyak C, Psomas C, Hill A, Gathogo EN, Trypsteen W, Vandekerckhove L, Kinloch S.

J Virus Erad. 2017 Apr 1;3(2):101-108.

31.

Erratum to: HIV integration sites in latently infected cell lines: evidence of ongoing replication.

Symons J, Chopra A, Malatinkova E, De Spiegelaere W, Leary S, Cooper D, Abana CO, Rhodes A, Rezaei SD, Vandekerckhove L, Mallal S, Lewin SR, Cameron PU.

Retrovirology. 2017 Mar 27;14(1):23. doi: 10.1186/s12977-017-0340-y. No abstract available.

32.

HIV Reservoir Characterization Symposium: 19 September 2016, Ghent, Belgium.

Malatinkova E, De Spiegelaere W, Vandekerckhove L, Sips M.

J Virus Erad. 2017 Jan 1;3(1):66-68.

33.

Corrigendum: Differential expression of lncRNAs during the HIV replication cycle: an underestimated layer in the HIV-host interplay.

Trypsteen W, Mohammadi P, Van Hecke C, Mestdagh P, Lefever S, Saeys Y, De Bleser P, Vandesompele J, Ciuffi A, Vandekerckhove L, De Spiegelaere W.

Sci Rep. 2017 Jan 24;7:41112. doi: 10.1038/srep41112. No abstract available.

34.

HIV integration sites in latently infected cell lines: evidence of ongoing replication.

Symons J, Chopra A, Malatinkova E, De Spiegelaere W, Leary S, Cooper D, Abana CO, Rhodes A, Rezaei SD, Vandekerckhove L, Mallal S, Lewin SR, Cameron PU.

Retrovirology. 2017 Jan 13;14(1):2. doi: 10.1186/s12977-016-0325-2. Erratum in: Retrovirology. 2017 Mar 27;14 (1):23.

35.

Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro post-integration latency models.

Bonczkowski P, De Scheerder MA, Malatinkova E, Borch A, Melkova Z, Koenig R, De Spiegelaere W, Vandekerckhove L.

Sci Rep. 2016 Dec 2;6:38329. doi: 10.1038/srep38329.

36.

Differential expression of lncRNAs during the HIV replication cycle: an underestimated layer in the HIV-host interplay.

Trypsteen W, Mohammadi P, Van Hecke C, Mestdagh P, Lefever S, Saeys Y, De Bleser P, Vandesompele J, Ciuffi A, Vandekerckhove L, De Spiegelaere W.

Sci Rep. 2016 Oct 26;6:36111. doi: 10.1038/srep36111. Erratum in: Sci Rep. 2017 Jan 24;7:41112.

37.

HIV-1 Vpr N-terminal tagging affects alternative splicing of the viral genome.

Baeyens A, Naessens E, Van Nuffel A, Weening KE, Reilly AM, Claeys E, Trypsteen W, Vandekerckhove L, Eyckerman S, Gevaert K, Verhasselt B.

Sci Rep. 2016 Oct 10;6:34573. doi: 10.1038/srep34573.

38.

The use of HIV-1 integration site analysis information in clinical studies aiming at HIV cure.

Kiselinova M, De Spiegelaere W, Vandekerckhove L.

J Virus Erad. 2016 Jul 1;2(3):175-6.

39.

Diagnostic utility of droplet digital PCR for HIV reservoir quantification.

Trypsteen W, Kiselinova M, Vandekerckhove L, De Spiegelaere W.

J Virus Erad. 2016 Jul 1;2(3):162-9.

40.

Highlights from the Conference on Retroviruses and Opportunistic Infections 2016: 22-25 February 2016, Boston, Massachusetts, USA.

Fidler S, Ananworanich J, Vandekerckhove L, Kiselinova M, Schuetz A, Vera JH, Dwyer E, Alagaratnam J.

J Virus Erad. 2016 Apr 1;2(2):124-30. No abstract available.

41.

Disparities in HIV clinic care across Europe: findings from the EuroSIDA clinic survey.

Lazarus JV, Laut KG, Safreed-Harmon K, Peters L, Johnson M, Fätkenheuer G, Khromova I, Vandekerckhove L, Maciejewska K, Radoi R, Ridolfo AL, Mocroft A.

BMC Infect Dis. 2016 Jul 20;16:335. doi: 10.1186/s12879-016-1685-x.

42.

Minimal Requirements for Primary HIV Latency Models Based on a Systematic Review.

Bonczkowski P, De Scheerder MA, De Spiegelaere W, Vandekerckhove L.

AIDS Rev. 2016 Oct-Dec;18(4):171-183. Review.

PMID:
27438577
43.

Aggressive extensive cardiac mass in an HIV-1-infected patient: should we go for comfort therapy?

Vervloet DM, De Pauw M, Demulier L, Vercammen J, Terryn W, Steel E, Vandekerckhove L.

Acta Clin Belg. 2017 Jun;72(3):198-200. doi: 10.1080/17843286.2016.1175703. Epub 2016 Jun 14.

PMID:
27355914
44.

The Future of Digital Polymerase Chain Reaction in Virology.

Vynck M, Trypsteen W, Thas O, Vandekerckhove L, De Spiegelaere W.

Mol Diagn Ther. 2016 Oct;20(5):437-47. doi: 10.1007/s40291-016-0224-1. Review.

PMID:
27351921
45.

Correction: Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth.

Kiselinova M, De Spiegelaere W, Buzon MJ, Malatinkova E, Lichterfeld M, Vandekerckhove L.

PLoS Pathog. 2016 Mar 22;12(3):e1005532. doi: 10.1371/journal.ppat.1005532. eCollection 2016 Mar. No abstract available.

46.

Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth.

Kiselinova M, De Spiegelaere W, Buzon MJ, Malatinkova E, Lichterfeld M, Vandekerckhove L.

PLoS Pathog. 2016 Mar 3;12(3):e1005472. doi: 10.1371/journal.ppat.1005472. eCollection 2016 Mar. Erratum in: PLoS Pathog. 2016 Mar;12(3):e1005532.

47.

Neuregulin-1 attenuates development of nephropathy in a type 1 diabetes mouse model with high cardiovascular risk.

Vandekerckhove L, Vermeulen Z, Liu ZZ, Boimvaser S, Patzak A, Segers VF, De Keulenaer GW.

Am J Physiol Endocrinol Metab. 2016 Apr 1;310(7):E495-504. doi: 10.1152/ajpendo.00432.2015. Epub 2016 Jan 19.

48.

Transmission of HIV Drug Resistance and the Predicted Effect on Current First-line Regimens in Europe.

Hofstra LM, Sauvageot N, Albert J, Alexiev I, Garcia F, Struck D, Van de Vijver DAMC, Åsjö B, Beshkov D, Coughlan S, Descamps D, Griskevicius A, Hamouda O, Horban A, Van Kasteren M, Kolupajeva T, Kostrikis LG, Liitsola K, Linka M, Mor O, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Staneková D, Stanojevic M, Van Laethem K, Zazzi M, Zidovec Lepej S, Boucher CAB, Schmit JC, Wensing AMJ; SPREAD Program, Puchhammer-Stockl E, Sarcletti M, Schmied B, Geit M, Balluch G, Vandamme AM, Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, Vandekerckhove LPR, Van den Heuvel A, Van Der Gucht B, Van Ranst M, Van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Van Laethem K, Beshkov D, Alexiev I, Lepej SZ, Begovac J, Kostrikis L, Demetriades I, Kousiappa I, Demetriou V, Hezka J, Linka M, Maly M, Machala L, Nielsen C, Jørgensen LB, Gerstoft J, Mathiesen L, Pedersen C, Nielsen H, Laursen A, Kvinesdal B, Liitsola K, Ristola M, Suni J, Sutinen J, Descamps D, Assoumou L, Castor G, Grude M, Flandre P, Storto A, Hamouda O, Kücherer C, Berg T, Braun P, Poggensee G, Däumer M, Eberle J, Heiken H, Kaiser R, Knechten H, Korn K, Müller H, Neifer S, Schmidt B, Walter H, Gunsenheimer-Bartmeyer B, Harrer T, Paraskevis D, Hatzakis A, Zavitsanou A, Vassilakis A, Lazanas M, Chini M, Lioni A, Sakka V, Kourkounti S, Paparizos V, Antoniadou A, Papadopoulos A, Poulakou G, Katsarolis I, Protopapas K, Chryssos G, Drimis S, Gargalianos P, Xylomenos G, Lourida G, Psichogiou M, Daikos GL, Sipsas NV, Kontos A, Gamaletsou MN, Koratzanis G, Sambatakou H, Mariolis H, Skoutelis A, Papastamopoulos V, Georgiou O, Panagopoulos P, Maltezos E, Coughlan S, De Gascun C, Byrne C, Duffy M, Bergin C, Reidy D, Farrell G, Lambert J, O'Connor E, Rochford A, Low J, Coakely P, O'Dea S, Hall W, Mor O, Levi I, Chemtob D, Grossman Z, Zazzi M, de Luca A, Balotta C, Riva C, Mussini C, Caramma I, Capetti A, Colombo MC, Rossi C, Prati F, Tramuto F, Vitale F, Ciccozzi M, Angarano G, Rezza G, Kolupajeva T, Vasins O, Griskevicius A, Lipnickiene V, Schmit JC, Struck D, Sauvageot N, Hemmer R, Arendt V, Michaux C, Staub T, Sequin-Devaux C, Wensing AMJ, Boucher CAB, van de Vijver DAMC, van Kessel A, van Bentum PHM, Brinkman K, Connell BJ, van der Ende ME, Hoepelman IM, van Kasteren M, Kuipers M, Langebeek N, Richter C, Santegoets RMWJ, Schrijnders-Gudde L, Schuurman R, van de Ven BJM, Åsjö B, Kran AB, Ormaasen V, Aavitsland P, Horban A, Stanczak JJ, Stanczak GP, Firlag-Burkacka E, Wiercinska-Drapalo A, Jablonowska E, Maolepsza E, Leszczyszyn-Pynka M, Szata W, Camacho R, Palma C, Borges F, Paixão T, Duque V, Araújo F, Otelea D, Paraschiv S, Tudor AM, Cernat R, Chiriac C, Dumitrescu F, Prisecariu LJ, Stanojevic M, Jevtovic D, Salemovic D, Stanekova D, Habekova M, Chabadová Z, Drobkova T, Bukovinova P, Shunnar A, Truska P, Poljak M, Lunar M, Babic D, Tomazic J, Vidmar L, Vovko T, Karner P, Garcia F, Paredes R, Monge S, Moreno S, Del Amo J, Asensi V, Sirvent JL, de Mendoza C, Delgado R, Gutiérrez F, Berenguer J, Garcia-Bujalance S, Stella N, de Los Santos I, Blanco JR, Dalmau D, Rivero M, Segura F, Elías MJP, Alvarez M, Chueca N, Rodríguez-Martín C, Vidal C, Palomares JC, Viciana I, Viciana P, Cordoba J, Aguilera A, Domingo P, Galindo MJ, Miralles C, Del Pozo MA, Ribera E, Iribarren JA, Ruiz L, de la Torre J, Vidal F, Clotet B, Albert J, Heidarian A, Aperia-Peipke K, Axelsson M, Mild M, Karlsson A, Sönnerborg A, Thalme A, Navér L, Bratt G, Karlsson A, Blaxhult A, Gisslén M, Svennerholm B, Bergbrant I, Björkman P, Säll C, Mellgren Å, Lindholm A, Kuylenstierna N, Montelius R, Azimi F, Johansson B, Carlsson M, Johansson E, Ljungberg B, Ekvall H, Strand A, Mäkitalo S, Öberg S, Holmblad P, Höfer M, Holmberg H, Josefson P, Ryding U.

Clin Infect Dis. 2016 Mar 1;62(5):655-663. doi: 10.1093/cid/civ963. Epub 2015 Nov 29.

49.

Aviremia 10 Years Postdiscontinuation of Antiretroviral Therapy Initiated During Primary Human Immunodeficiency Virus-1 Infection and Association With Gag-Specific T-Cell Responses.

Kinloch-de Loes S, Dorrell L, Yang H, Hardy GA, Yerly S, Cellerai C, Vandekerckhove L, De Spielgelaere W, Malatinkova E, Wee Lee Koh W, Johnson MA.

Open Forum Infect Dis. 2015 Nov 23;2(4):ofv144. doi: 10.1093/ofid/ofv144. eCollection 2015 Dec.

50.

During Stably Suppressive Antiretroviral Therapy Integrated HIV-1 DNA Load in Peripheral Blood is Associated with the Frequency of CD8 Cells Expressing HLA-DR/DP/DQ.

Ruggiero A, De Spiegelaere W, Cozzi-Lepri A, Kiselinova M, Pollakis G, Beloukas A, Vandekerckhove L, Strain M, Richman D, Phillips A, Geretti AM; ERAS Study Group.

EBioMedicine. 2015 Jul 21;2(9):1153-9. doi: 10.1016/j.ebiom.2015.07.025. eCollection 2015 Sep.

Supplemental Content

Loading ...
Support Center